COVID-19 Superinfection with Aspergillus spp. (COSIA)

• Conditions: U07.1; B44.0; COVID-19, virus identified; Invasive pulmonary aspergillosis

• Registration Number: DRKS00024578
• Lead Sponsor: Charité Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 215

Inclusion Criteria

severe case of Covid-19

Exclusion Criteria

no stay on intensive care unit

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint of the study is the risk factors for developing CAPA. The cohort will be retrospectively collected and analyzed after admission to an intensive care unit. Patients with definite CAPA infection will be randomly matched to controls without CAPA infection. Clinical and laboratory parameters will be collected and patients will be compared based on these parameters. It is an explorative nested-case-control study. The parameters will be collected from the hospital information system. <br>

Secondary Outcome Measures

Name	Time	Method
Dexametason as risk factor für CAPA.